The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Protocol Amendment History
32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2021-12-07; most recent amendment 2026-06-11.